Microbiotica, a leading player in microbiome-based therapeutics, today announces that Nigel Crockett, Head of Business Development, will participate in the Microbiome panel at the 23rd Annual International Partnering Conference, BIO-Europe, which will be held from 6-8 November, in Berlin, Germany.
Cambridge, UK, 25th October 2017 – Microbiotica, a leading player in microbiome-based therapeutics, today announces that Nigel Crockett, Head of Business Development, will participate in the Microbiome panel at the 23rd Annual International Partnering Conference, BIO-Europe®, which will be held from 6-8 November, in Berlin, Germany.
The discussion, entitled ‘Targeting the microbiome: From scientific evidence to regulatory approval‘, will take place on 6th November at 2.45 pm. The panel will discuss the therapeutic potential of this fast-growing field of research and the variety of strategies that companies have to choose from, as well as considering how companies select the best clinical and regulatory pathway for their products.
BIO-Europe® is Europe’s largest life science partnering conference; it provides a forum for companies across the biotech industry to meet and do business, through its range of workshops, exhibitions, panels and one-to-one meetings.
Microbiotica, spun-out of the Wellcome Trust Sanger Institute in 2016, was formed around ground-breaking research led by Dr Trevor Lawley and is focused on microbiome biology and its use in medicine, covering both novel bacterial therapeutics and patient diagnostics.
-ENDS-
Notes to Editors
About Microbiotica
- Microbiotica was established in 2016 to develop and commercialise ground-breaking research into the role of the human microbiome in health and disease and its application to medicine conducted in the Host-Microbiotica Interactions Laboratory (“HMIL”) at the Sanger Institute.
- Microbiotica’s founders are Mike Romanos, Trevor Lawley and Gordon Dougan, FRS.
- CIC and IP Group are co-investors in Microbiotica, with a £4m contribution from each party to provide total initial funding of £8m.
- Microbiotica is based at the Wellcome Genome Campus in Cambridge, UK, with offices in the Biodata Innovation Centre and laboratories in the Sanger Institute.
- www.microbiotica.com
About the Microbiome
Recognition of the importance of the microbiome, the body’s trillions of resident bacteria, represents a paradigm-shift in our understanding of its impact on human health and disease. This creates major opportunities in the diagnosis and treatment of a wide range of disease including enteric infections, autoimmune disorders, metabolic disorders, cancer and neurological disease.
For further information please contact:
Microbiotica
Rowena Gardner
+44 1223 786063 / +44 7801 480569
Instinctif Partners (for media enquiries):
Sue Charles/Gemma Harris
+44 20 7866 7860
